Hepatocellular Carcinoma, Immunotherapy
Conditions
Brief summary
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
Detailed description
Hepatocellular carcinoma exhibits a significantly elevated incidence and mortality rate in China. Despite the Chinese population representing a mere 18.4% of the global population, the annual incidence of new liver cancer cases reaches a staggering 466,000 (55.4% of the global total), with 422,000 deaths (53.9% of the global total). Immunotherapy, particularly the implementation of immunotherapy-based combination treatment regimens, holds substantial therapeutic value in the management of hepatocellular carcinoma (HCC), leading to notable breakthroughs and advancements in the comprehensive treatment of liver cancer. The aim of this study is to evaluate the safety and efficacy of immunotherapy-based combination treatment regimens in Chinese hepatocellular carcinoma (HCC) patients under real-world clinical conditions. By collecting and analyzing data on the etiology, clinical characteristics, treatment modalities, and treatment outcomes of HCC patients receiving immunotherapy-based combination treatments in the clinical healthcare setting, the study seeks to provide valuable information regarding treatment patterns and effectiveness for hepatocellular carcinoma patients.
Interventions
OTHERImmunotherapy-based Combination Therapies
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study.
Exclusion criteria
1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 24 months | All adverse events during the course of the study treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 24 months | From date of admission until the date of first documented progression in the real-world setting or date of death from any cause, whichever came first, assessed up to 24 months. |
| Disease control rate | 24 months | The percentage of subjects achieving complete response, partial response, or disease stability in a real-world clinical setting. |
| Objective response rate | 24 months | The percentage of subjects achieving complete or partial response in a real-world clinical setting. |
| Duration of response | 24 months | The time from the first documentation of objective response to the first assessment of progression in the real-world setting. |
| Overall survival | 24 months | From date of admission until the date of death from any cause, assessed up to 24 months. |
Countries
China
Contacts
Primary ContactXuehao Wang, professor
Backup ContactYongxiang Xia, professor
Outcome results
None listed